Intersect ENT to Present at the 38th Annual J.P. Morgan Healthcare Conference
Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at the Westin St. Francis Hotel in San Francisco, and will present at 1:30 p.m. PT.
A replay of the session will be available via the investors section of the company's website at www.intersectENT.com. The webcast replay will be archived for approximately one month.
About Intersect ENT®
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.
For additional information on the company or its products, including risks and benefits, please visit www.IntersectENT.com.
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2024.
Consolidated Financial...
WNS (Holdings) Limited , a leading provider of global digital-led Business Process Management (BPM) solutions, announced the filing of the Company's Annual Report on Form 20-F for the fiscal year ended March 31, 2024 with the United States Securities...
Remission Medical, the largest national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance, is now in its third year....
Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, the ongoing randomized, double-blind,...
The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava, MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits. In an article now appearing in the weekly publication, Srivastava is noted for...
A new Robotic Process Automation Data Quadrant Report from the global research and advisory firm showcases the leading RPA tools for 2024. Based on data from SoftwareReviews, the report identifies the top software providers that are empowering...
